The efficacy and Safety of non-vItamiN K antaGonist oraL anticoagulants for intermEdiate stroke risk in patients with Atrial Fibrillation (SINGLE AF study)

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0005141

Enrollment

1800

Registered

2020-06-17

Start date

2020-07-28

Completion date

Unknown

Last updated

2021-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : Arm1 Anticoagulation group(Apixaban group) apixaban component of drugs: Elxaban tab., Eliquis tab., Apiquis tab., Liquixia tab., Yuhanapixaban tab.. Dose: 2.5mg/5mg Regimen: twice daily Durati

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Age: 19~80 years old - CHA2DS2-VASc score 1 for male or 2 for female among nonvalvular atrial fibrillation patients - Patients who agree to register for this study - Patients who can be observed for the progress after treatment

Exclusion criteria

Exclusion criteria: - Severe liver or kidney dysfunction - Thyroid dysfunction - Pregnant or breastfeeding women - Malignant tumors that have not been completely cured - Severe structural heart disease - Predicted survival is less than 12 months - Patients who do not understand the content of the study or disagree with it

Design outcomes

Primary

Measure	Time frame
major bleeding and clinically relevant non-major bleeding	—

Secondary

Measure	Time frame
strokes;systemic embolism;mortality	—

Countries

Korea, Republic of

Contacts

Public ContactHyunsun Baek

Yonsei University Health System, Severance Hospital

cardiocrc13@yuhs.ac+82-2-2228-8528

Outcome results